Literature DB >> 31437485

Investigating the distribution of HIV-1 Tat lengths present in the Drexel Medicine CARES cohort.

Robert W Link1, Anthony R Mele2, Gregory C Antell1, Vanessa Pirrone2, Wen Zhong2, Katherine Kercher2, Shendra Passic2, Zsofia Szep3, Kim Malone3, Jeffrey M Jacobson4, Will Dampier1, Brian Wigdahl5, Michael R Nonnemacher6.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) encodes for Tat, a multi-functional regulatory protein involved in transcriptional enhancement and in causing neurotoxicity/central nervous system (CNS) dysfunction. This study examines Sanger sequencing of HIV-1 subtype B Tat from 2006 to 2014 within the Drexel University College of Medicine CNS AIDS Research and Eradication Study (CARES) Cohort to investigate Tat length in patients. The Los Alamos National Laboratory (LANL) database was used as a comparator. Miscoded stop codons were present in the CARES Cohort and LANL and protein variability was highly similar. Tat proteins in CARES and LANL were predominantly 101 residues. There was no observed correlation between Tat length and clinical parameters within the CARES Cohort. Unique Tat lengths found in the CARES Cohort and not in LANL were 31, 36, and 39 residues. When CARES patients were longitudinally examined, sequence lengths of 101 had a low probability of reducing to below 48, and sequences had a high probability of increasing to above 86 residues during their next visit, when below 48 residues in length. This suggests that Tat length is conserved to retain the majority of the proteins function highlighting its importance in viral replication.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetic variation; HIV-1; LANL; Stop codon; Subtype B; Tat

Mesh:

Substances:

Year:  2019        PMID: 31437485      PMCID: PMC6781634          DOI: 10.1016/j.virusres.2019.197727

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  38 in total

1.  Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues.

Authors:  L Hudson; J Liu; A Nath; M Jones; R Raghavan; O Narayan; D Male; I Everall
Journal:  J Neurovirol       Date:  2000-04       Impact factor: 2.643

2.  HIV-1 Tat protein mimicry of chemokines.

Authors:  A Albini; S Ferrini; R Benelli; S Sforzini; D Giunciuglio; M G Aluigi; A E Proudfoot; S Alouani; T N Wells; G Mariani; R L Rabin; J M Farber; D M Noonan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

3.  HIV-1 Tat is unconventionally secreted through the plasma membrane.

Authors:  Fabienne Rayne; Solène Debaisieux; Anne Bonhoure; Bruno Beaumelle
Journal:  Cell Biol Int       Date:  2010-03-12       Impact factor: 3.612

Review 4.  Implications of HIV diversity for the HIV-1 pandemic.

Authors:  Joris Hemelaar
Journal:  J Infect       Date:  2012-10-26       Impact factor: 6.072

Review 5.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

6.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

Authors:  L Naldini; U Blömer; F H Gage; D Trono; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Biopython: freely available Python tools for computational molecular biology and bioinformatics.

Authors:  Peter J A Cock; Tiago Antao; Jeffrey T Chang; Brad A Chapman; Cymon J Cox; Andrew Dalke; Iddo Friedberg; Thomas Hamelryck; Frank Kauff; Bartek Wilczynski; Michiel J L de Hoon
Journal:  Bioinformatics       Date:  2009-03-20       Impact factor: 6.937

8.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

9.  HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity.

Authors:  Michael R Nonnemacher; Vanessa Pirrone; Rui Feng; Brian Moldover; Shendra Passic; Benjamas Aiamkitsumrit; Will Dampier; Adam Wojno; Evelyn Kilareski; Brandon Blakey; Tse-Sheun Jade Ku; Sonia Shah; Neil T Sullivan; Jeffrey M Jacobson; Brian Wigdahl
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

10.  The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.

Authors:  Gilles Darcis; Caroline S Binda; Bep Klaver; Elena Herrera-Carrillo; Ben Berkhout; Atze T Das
Journal:  Viruses       Date:  2019-03-13       Impact factor: 5.048

View more
  4 in total

1.  GigaAssay - An adaptable high-throughput saturation mutagenesis assay platform.

Authors:  Ronald Benjamin; Christopher J Giacoletto; Zachary T FitzHugh; Danielle Eames; Lindsay Buczek; Xiaogang Wu; Jacklyn Newsome; Mira V Han; Tony Pearson; Zhi Wei; Atoshi Banerjee; Lancer Brown; Liz J Valente; Shirley Shen; Hong-Wen Deng; Martin R Schiller
Journal:  Genomics       Date:  2022-07-26       Impact factor: 4.310

Review 2.  The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.

Authors:  Hager Mohamed; Vandana Miller; Stephen R Jennings; Brian Wigdahl; Fred C Krebs
Journal:  J Immunol Res       Date:  2020-05-25       Impact factor: 4.818

3.  Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes.

Authors:  Kenneth Chen; Thienlong Phan; Angel Lin; Luca Sardo; Anthony R Mele; Michael R Nonnemacher; Zachary Klase
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

4.  HIV-1 Tat Length: Comparative and Functional Considerations.

Authors:  Anthony R Mele; Jamie Marino; Will Dampier; Brian Wigdahl; Michael R Nonnemacher
Journal:  Front Microbiol       Date:  2020-03-24       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.